|
|
Volumn 19, Issue 3, 2013, Pages 252-
|
|
Biotech comes to its ‘antisenses’ after hard-won drug approval
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTISENSE OLIGODEOXYNUCLEOTIDE;
APOLIPOPROTEIN;
MIPOMERSEN;
NUCLEOTIDE;
OBLIMERSEN;
OLIGONUCLEOTIDE;
B CELL LYMPHOMA;
BIOSYNTHESIS;
DRUG APPROVAL;
DRUG DELIVERY SYSTEM;
DRUG INDUSTRY;
FAMILIAL HYPERCHOLESTEROLEMIA;
HUMAN;
NOTE;
APOLIPOPROTEINS;
DRUG APPROVAL;
DRUG DELIVERY SYSTEMS;
DRUG INDUSTRY;
HUMANS;
HYPERLIPOPROTEINEMIA TYPE II;
LYMPHOMA, B-CELL;
OLIGODEOXYRIBONUCLEOTIDES, ANTISENSE;
OLIGONUCLEOTIDES;
THIONUCLEOTIDES;
|
|
EID: 84877244539
PISSN: 10788956
EISSN: 1546170X
Source Type: Journal
DOI: 10.1038/nm0313-252 Document Type: Article |
|
Times cited : (21)
|
|
References (0)
|